APGE · Apogee Therapeutics, Inc.
$134.72
+0.15 (+0.11%)
At close · Aug 19
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. ... Based on the Company's current operating plan, it estimates that its existing cash and cash equivalents of $105.6 million, marketable securities of $866.4 million and long-term marketable securities of $321.9 million as of June 30, 2026, will be sufficient to enable the Company to fund its operating expenses and capital requirements through at least the next 12 months from the issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$10.19B
Shares
75.69M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$255.84M
-40.5%
FY2025
Diluted EPS
-$4.22
-27.9%
FY2025
Operating Cash Flow
-$227.45M
-32.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $240.74M | $214.71M | $167.87M | $68.42M | |
| $83.01M | $70.88M | $49.01M | $24.58M | |
| $328.11M | $285.6M | $216.87M | $93M | |
| -$328.11M | -$285.6M | -$216.87M | -$93M | |
| $35.6M | $30.03M | $34.74M | $9.02M | |
| $34.02M | $30.03M | $34.74M | $9.02M | |
| -$294.09M | -$255.57M | -$182.13M | -$83.99M | |
| $280K | $278K | $18K | $0 | |
| -$294.37M | -$255.84M | -$182.15M | -$83.99M | |
| -$297.56M | -$255.68M | -$181.56M | -$83.66M | |
| USD/shares | — | -$4.22 | -$3.30 | -$3.36 |
| USD/shares | — | -$4.22 | -$3.30 | -$3.36 |
| shares | — | 60.69M | 55.19M | 25.01M |
| shares | — | 60.69M | 55.19M | 25.01M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 10.10×
EV/EBIT
—
Peer median 29.59×
P/E (TTM)
—
Peer median 19.39×
Peer medians compare against the 151 similar-size Biotechnology companies (of 546 listed).
Key facts
CIK
1974640
CUSIP
03770N101
13F (30d)
283 filings
281 filers
Visit website
Investor relations